Hemostasis is a physiological process to prevent and stop bleeding. Hemostasis involves three steps, which include vascular spasm (vasoconstriction), platelet plug formation, and coagulation. Some people are born with blood disorder disease (inherited diseases) such as Hemophilia and Von Willebrand disease. Hemophilia is a condition in which, blood does not clot properly due to lack of sufficient blood-clotting proteins (clotting factors), while Von Willebrand disease is caused due to the missing or defective clotting protein (von Willebrand factor).
Hemostasis valve is a device that is used to reduce risk of thromboembolism during neuroendovascular procedures. Guardian hemostasis valve is manufactured by Vascular Solutions Inc. and WATCHDOG hemostasis valve is manufactured by Boston Scientific Corporation are some examples of hemostasis valve. Moreover, hemostasis valve maximizes safety of the patient, reduces risk of air embolism, and blood loss.
Global Hemostasis Valve Market Drivers
The global hemostasis valve market growth is expected to surge over the forecast period, owing to increasing technological advances in hemostasis valves by manufactures. For instance, in 2017, new hemostasis valves HyperSeal and CertuSeal valves for the interventional and diagnostic catheters were introduced by the Freudenberg Medical. Additionally, Freudenberg Medical had introduced innovative FlexSeal valve in 2016. Moreover, for large bore procedure, Freudenberg Medical had introduced new HyperSeal Introducer Sheath with hydrophilic coating.
Furthermore, in May 2019, PhD (“Push, Hold, and Deliver”), which is a polycarbonate hemostasis control valve was launched by Merit Medical Systems, Inc. In addition, to operate the valve with one hand as well as to remove the diagnostic or interventional devices, PhD polycarbonate hemostasis control valve is used. Moreover, dual-seal PhD device is used to minimize the loss of blood without restricting device movement, and allows pressure injections up to 400 psi. These factors are expected to support global hemostasis valve market growth over the forecast period.
Global Hemostasis Valve Market Restraints
However, risk associated with the hemostasis valve such as air leakage that can cause air embolism is one of the major factors, which is expected to hamper growth of the global hemostasis valve market. For instance, in 2016, the U.S. Food and Drug Administration (FDA) recalled Guardian II Hemostasis Valves, manufactured by Vascular Solutions, Inc. This recall of Guardian II Hemostasis Valves was due to increased risk of air leakage that may cause an air embolism. Moreover, according to the U.S. FDA, the healthcare professional who have faced the problem of air leakage, should remove the product (Guardian II Hemostasis Valves) from their inventory and return them to vascular solution.
Global Hemostasis Valve Market Regional Analysis
North America is expected to account for largest market share in global hemostasis valve market, owing to factors such as increasing presence of key players and their involvement in the innovation associated with the hemostasis valve. For instance, in 2017, Qosina added four new Y-connecter hemostasis valve to its product line. Y-connector helps healthcare professional to handle hemostasis valve comfortably.
Growing prevalence of blood disorder disease is another factor that is expected to drive hemostasis valve market growth in North America. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2019, in the U.S., the number of patient suffering from the hemophilia was estimated around 20,000, based on the expected death and birth since 1994. Moreover, according to the same source, most of the patient suffering from hemophilia were diagnosed at young age only.
Europe is expected to exhibit highest CAGR over the forecast period due to increasing prevalence of hemophilia, which is a blood related genetic disorder. For instance, in 2018, according to WHO, in U.K., around 6,000 people suffered from hemophilia. In addition, according to the same source, in 2018, around 5,400 people suffered from hemophilia A while 1,100 people suffered from hemophilia B.
Global Hemostasis Valve Market Key Players
Key players operating in the global hemostasis valve market include Freudenberg Medical, LLC, Teleflex Incorporated, Boston Scientific Corporation, Argon Medical Devices., B. Braun Melsungen AG, Isla Lab Products LLC, SCW Medicath Ltd, Shenzhen Antmed Co.,Ltd., Galt Medical Corp., and Abbott Laboratories.
On the basis of type, the global hemostasis valve market is segmented into:
On the basis of applications, the global hemostasis valve market is segmented into:
On the basis of end user, the global hemostasis valve market is segmented into:
On the basis of region, the global hemostasis valve market is segmented into: